Investors
Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Karl Hård, Head of Investor Relations & Communications
[email protected] Phone: +46 733 011 944
Nicklas Westerholm, CEO
[email protected]
Yilmaz Mahshid, CFO
[email protected]
August 21, 2025
Interim Report Q2 2025 (7:00am CEST)
November 7, 2025
Interim Report Q3 2025 (7:00am CET)
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: [email protected]
